Valorization at the LCC
Contact: Myrtil Kahn, deputy director in charge of technology transfer, can be reached at 05.61.33.31.30 or myrtil.kahn(at)lcc-toulouse.fr.
The LCC conducts basic research on current societal issues. Its themes at the intersections of various fields, as well as its location on the Toulouse site, enable it to maintain long-term industrial partnerships with both small and medium-sized regional companies as well as large groups.
By including an upstream reflection on the potential applications of its work, the LCC leads a proactive approach open to this industrial fabric.
- The LCC has filed 43 patents in the last five years, including 1 declaration of invention; 14 priority patents; 25 patents accepted; and 3 patents licensed.
- The LCC has generated three start-ups: IMD-Pharma, DENDRIS, and Palumed.
In 2009, R. Fabre (Bio Pôle), J.M. François (PFBT, INSA) and J.P. Majoral (LCC, CNRS) decided to found Dendris in order to develop a new generation of in vitro diagnosis (IVD) kits. Therefore, Dendris SAS emerged from a scientific, technical and management cooperation and uses dendrimer-based DNA microarrays technology with an exclusive license from CNRS.
IMD-Pharma SAS (2016-) is developing a novel drug class for the treatment of Chronic Inflammatory Diseases (CIDs) like Multiple Sclerosis, Rheumatoid Arthritis and Psoriasis. These molecules show unprecedented control of inflammation and neuro-inflammation through selective, simultaneous binding to multiple membrane receptors and soluble mediators of myeloid cells.
The company was founded in 2016 by Serge Calet, Rémy Poupot and Cédric-Olivier Turrin (LCC).
PALUMED SA (2000-2017) (cofounded by B. Meunier) has developed four major therapeutic axes over the course of its 17-year history: dually active molécules against chloroquine-resistant Plasmodium falciparum sores, the development of specific trioxaquines for the treatment of bilharziosis, new antibiotiques to combat multi-resistant bactéries (neurosocomial diseases)